Bilaal.Raja
Company record

COLL  COLLEGIUM PHARMACEUTICAL, INC

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$683m
Revenue TTM
$808m
Net income TTM
$48m
Free cash flow
$328m
Composite score
89.2
Sector rank
#2189

Valuation

P / E
14.2
EV / EBITDA
1.4
EV / sales
0.7
FCF yield
48.09%
Yield vs 10-yr
1.74pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
5.9%
EBITDA margin
48.4%
ROE
15.4%
ROIC
86.3%
Revenue growth
14.3%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The $11.9 million increase is primarily due to increased revenue for Jornay PM of $13.4 million, Azstarys of $12.9 million, and Belbuca of $5.1 million, partially offset by the decreased revenue for Nucynta Products of $11.1 million, Xtampza ER of $7.6 million, and Symproic of $0.7 million. The increase in revenue for Jornay PM of $13.4 million is primarily due to higher sales volume, lower gross-to-net adjustments related to provisions for co-pay program incentives and product returns, and higher gross price, partially offset by higher gross-to-net adjustments related to provisions for rebates. …COLLEGIUM PHARMACEUTICAL, INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →